HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

• Main Authors: Saw Yen Ow (Author), Eugene A. Kapp (Author), Vesna Tomasetig (Author), Anton Zalewski (Author), Jason Simmonds (Author), Con Panousis (Author), Michael J. Wilson (Author), Andrew D. Nash (Author), Matthias Pelzing (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTHageman factor (FXII) is an essential component in the intrinsic coagulation cascade and a therapeutic target for the prophylactic treatment of hereditary angioedema (HAE). CSL312 (garadacimab) is a novel high-affinity human antibody capable of blocking activated FXII activity that is curren...